Published in J Clin Invest on March 01, 1999
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet (2000) 4.12
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord (2012) 1.13
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord (2015) 0.94
A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype. Hum Genet (2005) 0.93
Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed (2000) 0.84
No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov Disord (2015) 0.82
Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol Dis (2015) 0.78
Gaucher disease: when molecular testing and clinical presentation disagree -the novel c.1226A>G(p.N370S)--RecNcil allele. J Inherit Metab Dis (2011) 0.75
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
Supercoil sequencing: a fast and simple method for sequencing plasmid DNA. DNA (1985) 40.01
The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA. Nucleic Acids Res (1985) 12.11
Determination of nucleotide sequences in DNA. Science (1981) 6.02
The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA. Nucleic Acids Res (1985) 3.65
The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics (1989) 3.10
Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Natl Acad Sci U S A (1985) 2.82
Suggestions for "safe" residue substitutions in site-directed mutagenesis. J Mol Biol (1991) 2.80
A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med (1987) 2.77
Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature (1992) 2.04
Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet (1989) 1.97
Collodion babies with Gaucher's disease. Arch Dis Child (1988) 1.60
Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest (1994) 1.58
Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J Biol Chem (1994) 1.52
Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol (1997) 1.49
Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr Res (1992) 1.43
A glucocerebrosidase fusion gene in Gaucher disease. Implications for the molecular anatomy, pathogenesis, and diagnosis of this disorder. J Clin Invest (1990) 1.41
Complex alleles of the acid beta-glucosidase gene in Gaucher disease. Am J Hum Genet (1990) 1.41
Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting. Am J Hum Genet (1987) 1.38
Sphingolipids are required for mammalian epidermal barrier function. Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J Clin Invest (1991) 1.32
Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function. J Clin Invest (1993) 1.23
Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc Natl Acad Sci U S A (1998) 1.23
Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J Biol Chem (1993) 1.21
Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients. Am J Med Genet (1985) 1.21
Prevalent and rare mutations among Gaucher patients. Gene (1990) 1.17
Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol (1997) 1.17
Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine. Am J Hum Genet (1985) 1.17
Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher's disease. Pediatr Res (1998) 1.16
Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. Am J Hum Genet (1993) 1.16
Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol (1990) 1.16
Complete mutagenesis of protein coding domains. Methods Enzymol (1991) 1.16
Prenatal lethality of a homozygous null mutation in the human glucocerebrosidase gene. Am J Med Genet (1997) 1.14
Heterogeneity of mutations in the acid beta-glucosidase gene of Gaucher disease patients. DNA Cell Biol (1991) 1.11
Quantitative immunoassay of adenosine deaminase in combined immunodeficiency disease. J Immunol (1977) 1.08
Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J Biol Chem (1997) 1.08
Polymorphisms in the human glucocerebrosidase gene. Genomics (1992) 1.08
Expression of mutated glucocerebrosidase alleles in human cells. Hum Mol Genet (1997) 1.06
Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res (1996) 1.01
Synthesis of a fluorescent derivative of glucosyl ceramide for the sensitive determination of glucocerebrosidase activity. Anal Biochem (1984) 0.99
beta-Glucocerebrosidase activity in murine epidermis: characterization and localization in relation to differentiation. J Lipid Res (1992) 0.98
Gaucher disease associated with a unique KpnI restriction site: identification of the amino-acid substitution. Ann Hum Genet (1990) 0.97
Long-range structural effects in a second-site revertant of a mutant dihydrofolate reductase. Proc Natl Acad Sci U S A (1993) 0.96
New perspectives in type 2 Gaucher disease. Adv Pediatr (1997) 0.96
Comparison of the chromosomal localization of murine and human glucocerebrosidase genes and of the deduced amino acid sequences. Proc Natl Acad Sci U S A (1989) 0.94
A second-site mutation at phenylalanine-137 that increases catalytic efficiency in the mutant aspartate-27----serine Escherichia coli dihydrofolate reductase. Biochemistry (1990) 0.94
Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes. Am J Hum Genet (1991) 0.92
Non-existence of a tight association between a 444leucine to proline mutation and phenotypes of Gaucher disease: high frequency of a NciI polymorphism in the non-neuronopathic form. Hum Genet (1990) 0.90
Clinical heterogeneity among patients with Gaucher's disease. JAMA (1993) 0.90
The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease. J Med Genet (1996) 0.90
Three unique base pair changes in a family with Gaucher disease. Hum Genet (1991) 0.89
The glucocerebrosidase D409H mutation in Gaucher disease. Biochem Mol Med (1996) 0.89
Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients. J Clin Invest (1997) 0.88
Congenital ichthyosis preceding neurologic symptoms in two sibs with type 2 Gaucher disease. Am J Med Genet (1995) 0.88
Gaucher disease: four rare alleles encoding F213I, P289L, T323I, and R463C in type 1 variants. Hum Mutat (1992) 0.87
Human acid beta-glucosidase: glycosylation is required for catalytic activity. Biochem Biophys Res Commun (1990) 0.87
Collodion babies with Gaucher's disease--a further case. Arch Dis Child (1991) 0.85
Congenital ichthyosis with restrictive dermopathy and Gaucher disease: a new syndrome with associated prenatal diagnostic and pathology findings. Obstet Gynecol (1993) 0.82
Mutations in two specific residues of testicular angiotensin-converting enzyme change its catalytic properties. J Biol Chem (1993) 0.81
Molecular characteristics in Japanese patients with lipidosis: novel mutations in metachromatic leukodystrophy and Gaucher disease. Mol Cell Biochem (1993) 0.81
Gaucher disease associated with congenital ichthyosis in the neonate. Eur J Pediatr (1995) 0.80
Gaucher's disease: genetic counselling and population screening. Baillieres Clin Haematol (1997) 0.76
Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med (2001) 6.94
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science (1996) 4.22
Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med (2001) 3.72
Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro. Mol Cell Biol (1989) 3.00
Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet (2001) 2.81
Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med (1998) 2.80
Mutagenesis by transient misalignment. J Biol Chem (1988) 2.66
Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet (1995) 2.66
Growth and neurodevelopmental outcome of VLBW infants at 1 year corrected age. Indian Pediatr (2012) 2.64
Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A (1986) 2.51
Regional gene assignment of human porphobilinogen deaminase and esterase A4 to chromosome 11q23 leads to 11qter. Proc Natl Acad Sci U S A (1981) 2.50
Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med (1973) 2.35
An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med (1991) 2.27
Human delta-aminolevulinate dehydratase: nucleotide sequence of a full-length cDNA clone. Proc Natl Acad Sci U S A (1986) 2.25
Exonucleolytic proofreading enhances the fidelity of DNA synthesis by chick embryo DNA polymerase-gamma. J Biol Chem (1988) 2.16
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet (2001) 2.13
Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet (2000) 2.08
Quality assurance in molecular genetic testing laboratories. JAMA (1999) 2.00
Purification and properties of delta-aminolevulinate dehydrase from human erythrocytes. J Biol Chem (1979) 1.89
Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J Biol Chem (1991) 1.89
Purification and properties of uroporphyrinogen I synthase from human erythrocytes. Identification of stable enzyme-substrate intermediates. J Biol Chem (1980) 1.87
Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet (1993) 1.83
The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. N Engl J Med (1989) 1.79
Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A (1988) 1.79
Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med (2001) 1.73
Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr Res (1984) 1.67
Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet (1999) 1.62
The delta-aminolevulinate dehydratase polymorphism: higher blood lead levels in lead workers and environmentally exposed children with the 1-2 and 2-2 isozymes. Environ Res (1991) 1.62
Prader-Willi syndrome and a bisatellited derivative of chromosome 15. Clin Genet (1980) 1.60
Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet (1990) 1.57
A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab (2009) 1.55
Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. EMBO J (1989) 1.55
Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet (1994) 1.52
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis (2003) 1.52
Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol (1997) 1.50
The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis (2009) 1.50
Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J Cell Biol (1992) 1.49
Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. J Biol Chem (1996) 1.49
Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet (2000) 1.48
Characterization of Hex S, the major residual beta hexosaminidase activity in type O Gm2 gangliosidosis (Sandhoff-Jatzkewitz disease). Am J Hum Genet (1975) 1.46
Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest (1989) 1.44
A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group. N Engl J Med (1992) 1.43
Prenatal genetic carrier testing using triple disease screening. JAMA (1997) 1.43
Regional assignment of the human acid sphingomyelinase gene (SMPD1) by PCR analysis of somatic cell hybrids and in situ hybridization to 11p15.1----p15.4. Genomics (1991) 1.43
Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms. J Biol Chem (1981) 1.42
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis (2008) 1.41
Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science (1970) 1.41
Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther (2011) 1.39
Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting. Am J Hum Genet (1987) 1.38
Cardiopulmonary arrest secondary to haloperidol. Am J Emerg Med (2000) 1.38
Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology (2006) 1.37
Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res (1989) 1.37
Alpha-L-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I. Pediatr Res (1979) 1.36
Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med (1997) 1.36
Invariant exon skipping in the human alpha-galactosidase A pre-mRNA: Ag+1 to t substitution in a 5'-splice site causing Fabry disease. Genomics (1992) 1.35
Effect of the delta-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res (1998) 1.35
Cytogenetic results from the U.S. Collaborative Study on CVS. Prenat Diagn (1992) 1.35
Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet (1991) 1.35
Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. J Med Genet (2003) 1.34
Human delta-aminolevulinate dehydratase: chromosomal localization to 9q34 by in situ hybridization. Hum Genet (1987) 1.32
Niemann-Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. J Clin Invest (1991) 1.32
Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest (2001) 1.31
Mannosidosis: clinical, morphologic, immunologic, and biochemical studies. Pediatr Res (1976) 1.31
Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat Genet (1995) 1.30
Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat (1994) 1.29
Fabry disease: detection of gene rearrangements in the human alpha-galactosidase A gene by multiplex PCR amplification. Hum Mutat (1993) 1.29
Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene. J Biol Chem (1990) 1.28
Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med (2000) 1.27
Niemann-Pick disease: a frequent missense mutation in the acid sphingomyelinase gene of Ashkenazi Jewish type A and B patients. Proc Natl Acad Sci U S A (1991) 1.25
The ocular manifestations in Fabry's disease. Arch Ophthalmol (1979) 1.25
Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem (1995) 1.23
Toward enzyme therapy for lysosomal storage diseases. Physiol Rev (1976) 1.23
Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest (1999) 1.23
delta-Aminolevulinic acid dehydratase isozymes and lead toxicity. Ann N Y Acad Sci (1987) 1.22
Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria. Immunologic evidence for heterogeneity of the genetic defect. J Clin Invest (1981) 1.22
Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci U S A (1979) 1.21
Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology (1999) 1.21
Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients. Am J Med Genet (1985) 1.21
Gaucher disease: expression and characterization of mild and severe acid beta-glucosidase mutations in Portuguese type 1 patients. Eur J Hum Genet (2000) 1.21
Delta-aminolevulinic acid dehydratase polymorphism: influence on lead levels and kidney function in humans. Arch Environ Health (1997) 1.20
Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site. Proc Natl Acad Sci U S A (1986) 1.20
The pathology of the feline model of mucopolysaccharidosis I. Am J Pathol (1983) 1.20
Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab (1998) 1.19
Genetics of peanut allergy: a twin study. J Allergy Clin Immunol (2000) 1.19
Assignment of the gene for acid beta-glucosidase to human chromosome 1. Am J Hum Genet (1981) 1.19
Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. J Biol Chem (1987) 1.19
Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length cDNA, and regions of amino acid identity with arylsulfatases A and C. Genomics (1990) 1.19
Chronic GM2 gangliosidosis masquerading as atypical Friedreich ataxia: clinical, morphologic, and biochemical studies of nine cases. Neurology (1981) 1.18
An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue. J Clin Pathol (2005) 1.18
Mannosidosis: pathology of the nervous system. J Neuropathol Exp Neurol (1977) 1.17
Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase (SMPD1). Genomics (1992) 1.17
Neuroaxonal dystrophy due to lysosomal alpha-N-acetylgalactosaminidase deficiency. N Engl J Med (1989) 1.17
Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol (1981) 1.17
Gaucher disease: the N370S mutation in Ashkenazi Jewish and Spanish patients has a common origin and arose several thousand years ago. Am J Hum Genet (1999) 1.17
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet (2008) 1.16
Glutamate dehydrogenase deficiency in three patients with spinocerebellar syndrome. Ann Neurol (1980) 1.16
Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal Biochem (1999) 1.16
Metachromatic leukodystrophy without arylsulfatase A deficiency. Pediatr Res (1979) 1.15
Purification and properties of uroporphyrinogen III synthase from human erythrocytes. J Biol Chem (1987) 1.15